Worldwide CAR-T cell therapies market is gaining significant growth in North America
Worldwide CAR-T cell therapies market is
gaining significant growth in North America
Market Overview:
CAR-T cell therapies
is advanced cancer therapy and is highly preferred over surgery, chemotherapy,
and radiation. These target cancer cells and strengthen the patient’s immune
system against the tumor.
The global Car TCell therapy market is estimated to be valued at US$ 1,085.0 million in 2021
and is expected to exhibit a CAGR of 24.5% during the forecast
period (2021-2028).
Key Drivers
According to the
World Health Organization, cancer is a leading cause of death worldwide,
accounting for nearly 10 million deaths in 2020. There is a high prevalence of
cancer around the globe. Growing number of patients showing failure response to
the alternative cancer treatments is a prime factor driving growth of the CAR T
cell therapy market.
Increasing development of development of new and effective therapy options to cure cancer is again driving growth of the market growth. For instance, in July 2020, Kite, a Gilead Company announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Tecartus™ (brexucabtagene autoleucel, formerly KTE-X19), the first and only approved chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
Comments
Post a Comment